A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms CENTERA
- Sponsors Bayer
- 25 Aug 2016 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
- 25 Aug 2016 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.
- 25 Aug 2016 Status changed from not yet recruiting to recruiting.